N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Sustained minimal residua" (30 stories)

Top Headline Story

Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy
Lead StoryFrontiersgeneral
Aug 28

Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQdEVRN0RsVm53cXMtVjhLM0RtT181alJZbk9ueU9udWhaNXZZVU1zTzBlVUhzTVA0Uld6UEZaSEdqdl9EYTZPcmU3eEZ1X2oyVEs5Q0tWZjB6QURSNm56OHRNRGdILUhwTUxnZDlCWWhRcERTaEpqSDcxUjhheGhWUG1qem1WVHpLVmlUR1pZN3Nodw?oc=5" target="_blank">Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+24m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+24m ago

pope francis

The Myth of St. Francis

Filter stories
500+34m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+34m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "Sustained minimal residua"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)
OncLivetech

Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)

<a href="https://news.google.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?oc=5" target="_blank">Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?
Medscapetech

Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPY19INU9XTHFjVk9NdHRtVzYwal91WVVkZHJyWG5BcFpoaXZ3ajBMT3J1T28xdXpOX0ZEWWxSWW1uYTAzak10VWhqS25BSFZPazk1NE9JclBjdVNxb0c2dDJUcEpwdC1JX1FKX1YwSkY1QVhaLVEtdjd5dVZDclFQRVRhSGU4WEw4ODk3NWN1UzIwYWcyM2Y4R3REZGozbko2R1RjLTlB?oc=5" target="_blank">Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Daratumumab Maintenance More Than Doubles Median PFS in Long-Term CASSIOPEIA Analysis
Pharmacy Timestech

Daratumumab Maintenance More Than Doubles Median PFS in Long-Term CASSIOPEIA Analysis

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNYlIyRXFUZ0FSUFlSYVc1bXVSZkdiQ19FX0Y4T0RzMlJXTG1WVjRzUnNIRk5rTEh4TWdrbEhvai02MEdmZUpzLWx3RndsQkVHS0JjM0lrWFRUT2xGaEF3VlBDcGNBWWZNMHNMSHJCT0JxeU5KUy12bTVMVkNGYU9Id3B2SVlBTGw3M2RDSUN1UjB0enhWdkNEcnBkUUdmV1VwZ0ZHdjFuLW1zNFh2RWVBaFV1WUstdzBBamFkNg?oc=5" target="_blank">Daratumumab Maintenance More Than Doubles Median PFS in Long-Term CASSIOPEIA Analysis</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Minimal Residual Disease Testing Market Size, Share & Growth 2026-2035
SNS Insidermarkets

Minimal Residual Disease Testing Market Size, Share & Growth 2026-2035

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNVFN1OVVjLWZTRFlXRDhKc29hTzFZdURsRnVXNzVLZk53S3lSbkFsVkRLOTlOZjlZTWN3eWZZOUxrUm14WUNuSDJNbmRnWGpEMGhFcXFsWlZGQ3FkUy11Z1R1ck80My1sMDQwNUM4VER3WXd6eXhjejNoWFQ3aDRZYWJ2bTFjUQ?oc=5" target="_blank">Minimal Residual Disease Testing Market Size, Share & Growth 2026-2035</a>  <font color="#6f6f6f">SNS Insider</font>

Read Full StoryMore like this
Rest-Of-Asia-Pacific Minimal Residual Disease Market Size, Share,Trends, Growth Analysis Report, 2029
MarketsandMarketsmarkets

Rest-Of-Asia-Pacific Minimal Residual Disease Market Size, Share,Trends, Growth Analysis Report, 2029

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZkF6Q0RRN0FaeE5fLVZNd3l0NlBuNjgzNF9HU1A2VktRTThvYzc2RFVkZERpam1RLWVDc2VSZGJZT2VuQVQ4cXZGUWJXSnlHUTBaakpIeEI0TXlfSUdoWW9yTnZJdVRZVkJrVVNIU3pIeEZaQkRpME5Yb29LeE9tSGtCRmRvV19vdWFpbkQyTHV3VUlwZUZGcDVxb0ZKdm5RRk1sTVpxUlF6VWdxS1RObjhBQW1KMlg5cjBJ?oc=5" target="_blank">Rest-Of-Asia-Pacific Minimal Residual Disease Market Size, Share,Trends, Growth Analysis Report, 2029</a>  <font color="#6f6f6f">MarketsandMarkets</font>

Read Full StoryMore like this
Persistent BCR::ABL1 p190 Minimal Residual Disease and Declining Donor Chimerism Following Haploidentical Bone Marrow Transplant in Pediatric Acute Myeloid Leukemia With Dual High-Risk Fusions
The Cureus Journal of Medical Sciencegeneral

Persistent BCR::ABL1 p190 Minimal Residual Disease and Declining Donor Chimerism Following Haploidentical Bone Marrow Transplant in Pediatric Acute Myeloid Leukemia With Dual High-Risk Fusions

<a href="https://news.google.com/rss/articles/CBMizgJBVV95cUxPUGRvU2std2JGMUR5bF8tTnlZU01SWkhIem1hZng2eWRtUkk1bTdKUWVJajRHM3E3OHNkWk00OV8wUXI2TExlMUkxV2NnN3ZDakZia1V3by01eVVYdGVHdnQzZzdjN3JMN0I4MnREZ3Y2QVBnYkJtRFpoUTFHelhjSDd0WlE3c1dUbHBqMHZyYXJ3NEtDZjd0ZjlRNnJNdjRsOFB6V0pSbERDUzBWSzJHTm5wZmtObTE2LWJYU3NNMTV4N0thOGdaRHE5LUpXU0czVk4xSXZOY0V2MGNQNEZfXzBDbnNnQmJlT1RHalZpbHZHZktVdkdvTVJyWUd2Mk9ybTRfM25WaXZIZ0tpQWx3OWRuTnd1MjVYa1lxV2I4VWNaZlduSzlValY5V3BWTTJ0WXEzTmdKT0FGRmJJU1NzTFFmSnVGWVk4Zm9NNTln?oc=5" target="_blank">Persistent BCR::ABL1 p190 Minimal Residual Disease and Declining Donor Chimerism Following Haploidentical Bone Marrow Transplant in Pediatric Acute Myeloid Leukemia With Dual High-Risk Fusions</a>  <font color="#6f6f6f">The Cureus Journal of Medical Science</font>

Read Full StoryMore like this
Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma
Targeted Oncologytech

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNdVo2WGhIMlBsV3BuTHdYaVNhWW1UcTFiRjJ2Rmt2RWsxbzY4QlZwNExaUU93ZURCX1FnN2dTcVVmeHhfM0lZME9UOXZlRE8zc1R0WEszc1dyTUkzR2p3Z0NHcGw3aHJSQ212QmllNmVUdVdrcVFZMnQzcFFRUmhnMkQ1dDhtT0dtbU9NSEVRcHNVZGZrcUN2MnVER3g5aGRhcWZORlhLSUJZUFoxMnVEckVR?oc=5" target="_blank">Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients
Oncology News Centraltech

Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPN1pUZk9hX1lrcmNadGY1WVdHQUM2eTlSZWxXcnhpaGQyVWtsdXBObUxaMndnU0p2ZnhtWkVjVHRFLTRtMjY2T0t5MTM2WkVJUVp2S3FKZzV2SjZqZ09jWmJVV0RiTmI3SVMzUmlHdFVKaXhpS2lPRUpnSUxMYUlraVNaZnEwS0N2cUtOR1FvUzBUWDNEaGUzZVpMNHl0elJUQ3FxYUVQYkpscVNxdDVFcHpRQ3U5Mkd4VXQ5b2NXVEVwYVJva2hYTW16UnNFcHRLVGc?oc=5" target="_blank">Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) | Blood Cancer Journal
Naturetech

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBJck5IOG84NFMzdElpNXV0bVNFd1RiV2s4cWVXMEFMbURaMkZhM0h4ck8yTl9ZdlYzUEFvZjAzdU9uUWZMTDU1RzIxZUVya08tUk94QTNFbzJPZWtsWjY0?oc=5" target="_blank">Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM
Pharmacy Timesgeneral

Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOTWlOS01laGhvM0U0Q3RTdDBQdmdoNGp0dGFWWEFhS1hVUUtGdUxiRUJ0TzlRam1uY0I2R1ZCTkp6T0stOUhHUWd3eFFOeU5zX1VmeWRnY1hCdkpfcG1oN0s2VllBTHdWamt6dU9MS2NhYTlfM2lFd3dWM29Bc0RDSVJzUjRJeTMwNFIwOHBKN2JYQ2JHeDdFSUlabmZVTzQ0T3B6Y2ZnNzFJcll6ZHhJeFkxQXpXMXhQZkE4QnIzMA?oc=5" target="_blank">Long-Term BENEFIT Data Affirm Isa-VRd as Standard of Care in Transplant-Ineligible NDMM</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma
2 Minute Medicinetech

VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

<a href="https://news.google.com/rss/articles/CBMisgJBVV95cUxNdl81V3JhOVp5Z3VuX2pWbDBkemcySldkWXV6T0JDMFo1NlpBN0YtcGZ0SmlXbUVnT2ZvRlI0UlJBd081LTNlVHdab2NVRDBmNUx2M0NKMW1EdXBzWTJpbHVOQW84UUNVekNnc3MyQUJsbjZlMlRZN1N3bXpWQXIxcWpwclRNUC02N1lWamY3SGlSS3Mwb0RiWEhkOTJHZ0lTdWdWSHRzdlpyRkZhNDVfSkJxM0tMSmtZcGwzMHZFSWJ6MDdZUjNuSDNqcGRhR0tSaVBwVTlHZmIyZ241UldBZkJPNE9tMjI4SWhHRF9SU2hXLWtROU9pZVN5bi1admIwUC0tSmlDTUtBSzNhRTVJOUtud0M1ODBQZjNXUmZ3dzZzRmFYUXVaNF81SWwyV04xVkE?oc=5" target="_blank">VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma</a>  <font color="#6f6f6f">2 Minute Medicine</font>

Read Full StoryMore like this
Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025
OncLivegeneral

Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNSnU5dW5Nc25IVmpBTnBaWmx2Ym8xS3FUMkUtOEp2SkVLTDhacHNadUNhdEFhMHBYelMwUHRUQlFuS2ZCUFZ0M1AxWTJQSmVidDJjWmZGMUdoa0hYZmpzSG41bEZJVVFqeGlmdnRGMjJidURaZlJmM0d6UVlJX3JPVmgwTjFrd21vZXJaYkVQRE5iWVFFYXc?oc=5" target="_blank">Previewing Top Myeloma Abstracts Set to Make Waves at ASH 2025</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Minimal Residual Disease Status in Multiple Myeloma: Can Its Use Reveal the Path to a Cure?
ASCO Daily Newsgeneral

Minimal Residual Disease Status in Multiple Myeloma: Can Its Use Reveal the Path to a Cure?

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOWTVOQ05FbkhMRmo1UFQ3LU42YVg4dHZNS25zNVVFclNldWlob18yWWVMOG5CN2NTOUlidVExamxZNFBhSGFIcHA1YTh3U3pqbGZyUDZUNFpEWlRMRFlVdmdGcmc3SF82ZkJyWi1idlNkZlY0VzN6cXp6XzhpaGxaZDNoQnBEX0E0YWVmMWs2VUVieDkzWTlfT2F6ZU9rM2V6WFB5anZ0dFF5Rlp2WHlnMA?oc=5" target="_blank">Minimal Residual Disease Status in Multiple Myeloma: Can Its Use Reveal the Path to a Cure?</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients | Blood Cancer Journal
Naturegeneral

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXWnU3NXhYQmVfVE5jUFhOR21PZ2M1MHAwN0tlUFQ1UHRrMU5lbFBydjVoR0tTcTh2YVdBMVlFNWRRQmtvX192WkNXNlFsdGlNdU1aWm8wZm9IT3ZYSHBn?oc=5" target="_blank">Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy
Targeted Oncologytech

Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ00weFVmR00zUktRT1RnUVF1aHlXdVdPN1Jrd2lqUE1heWxHYzNCRG1QNUctMm5XcEtfVlY5c0R3T3J1WnBsQmVnX3FzOW5VSkN3TEkwSVZLT0RwMVVWUkhBcjVud2VBaG1PdmdMVUFjTXVZTVI2RXNRTXBjNFRVZ0hHemNKeFFaeDRhcHhqM0dzYWxzT3JtYldtbUpzaWFx?oc=5" target="_blank">Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Frontiersgeneral

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNb0NLbURiR1J0WmxnVDNDT3FaN0ctbnV6dFh3Zl9Fdjh3YmlsZWt2LUFzY3RHUGpVWE9UenUtcHc3YVhkQUF1bk5US3ZXRURxQUxBNTlqX0RINFBzeHpTUWMtRC1vYWd1RGpKLUctU1ZIRnR4SGlMcjRHZVZOQmRVWFRwUzFBWnhBVnNv?oc=5" target="_blank">Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
Naturetech

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBvdGFONXNEZjFXNTJ6dnhSeWJzU3RTVU1fRzl1Z21yaTZ5dndNNmJVLXRubUs5ZUJhLUpGek9TcWxhSTlvemc3aV8yUmtQNmdBV3J1cFhaNzZUZU04NmZZ?oc=5" target="_blank">Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma
OncLivegeneral

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPeFM3QlFaMDZEWE1JcjBjeG1FdDVQOFZ3Vy1fWTNNNldUREg0bDBRdnQwVDBBdVQxM2tvbGRlUG9EV1NKMlZEVkhsWTJnUE8xd2V1UnBXNkNaaHAtSGlZemhaVklaRFA3N3RwUGIyQlJfaDJ0RjE2YVp0a1JzVVVjRllnWDYxUkw5SldhSGJPbFJSOFlQM2ZtanJxTDVtaERuT3ZkVWpwN2M4SWpjTVE?oc=5" target="_blank">D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer
Natureworld

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE11SXRoa2lGNDZSYVF2SlpJRmh0c1B6WEJBV0RSektXRGNQMkI4RlpCNGhXekMtSlNISldUSnVSYmxHRFI5cGJsQzEySVZnRnFWa1p0TmVaVE9qVXdZcFpr?oc=5" target="_blank">A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
IMS Day 2 Recap: MRD-Guided Maintenance, Novel Bispecific Data in Myeloma
Targeted Oncologytech

IMS Day 2 Recap: MRD-Guided Maintenance, Novel Bispecific Data in Myeloma

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOeFllX2szel95TmIxTlcwMFh2XzR1TTd2WnhUU2o0WnFTRlFmbjJ2dEROcVV4M2Z4blhWTi1kQjhwdzJZVUVwT29JdjhHQU43WkxLTEZ5clpEZk5wVFVhS2hHNzBPZU15eWFwWDhwU211dzVQeDR6WUdpTjFrYk9BUTJpdzBHQzd5QWFMd2MwTElGR0VjelpaUTB2NjNOM3lvTFg1SWJmQQ?oc=5" target="_blank">IMS Day 2 Recap: MRD-Guided Maintenance, Novel Bispecific Data in Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1
OncLivetech

Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxOOHEwM19POW5sSGcyQjMxNlN6a292OV93WnFQZ2Qzbko0OWxNSWM0aWgzem5iaFRqNUhYa1FPOFBwLUhZSDZJU2tZbE9nNHhKRHRWbmw4S2NNaDVlS1U4THNTWDF0YkFDUExFRThveTRRbF9GX3laVjBMTWpRdWZZZG9WUXdWb01lUGctY3prUmJVN2NUNXNnM2x4YWRlYS15cWltZGE5cE13anlLUmR0d1lNaXNXZmtYWV9lWFpma2tKaWhaN1JEeTNwcGZ3NEhGMUE?oc=5" target="_blank">Dr Lin on the Characteristics of Patients With Multiple Myeloma and Sustained MRD Negativity in CARTITUDE-1</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
Frontiersgeneral

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQR1M0eHU4RW1UVmFIUG9aOFhUUjNBQ1hOYWJlaHRuXzExcTlSdjJQQjBwczlyTnF1em9uSmpCQ2ZGUXJIYXVZT19idi1TaTN5bmN2MGhEUTlDc2xKbmxwWDFJMjQzNXJOTjRteWxDcWhySC1ET3Z3ODNqdWVjTnBZU0oxaVdmTnlINXgyQQ?oc=5" target="_blank">Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Sustained MRD negativity after CAR-T improves outcomes in multiple myeloma
Healiotech

Sustained MRD negativity after CAR-T improves outcomes in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOekJFWW40QzRFbjFBMW5yS1EyZEhDREZLRFhGRDhwRzA4dHZOREJDblA1VWJpaWNkT0hMVHl0UEZDVFR4enhvdWd2U1Q1SGVRY3BBMFRmTXJHTDVETmtDSjVXSUNlSkNLR25QTzJSM1ZIcENUMFFPcE9MSWxUOS11ODN4VkpCNWZqYmtBa2FQbTEwbWJnNHg0RWtqaW44TG91dVlLbVVQbEZfMEwtTFVvOG1kTUdaWjYyNl85SWVOVUhDbVlkWGhEcnNn?oc=5" target="_blank">Sustained MRD negativity after CAR-T improves outcomes in multiple myeloma</a>  <font color="#6f6f6f">Healio</font>

Read Full StoryMore like this
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
Targeted Oncologygeneral

IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxONDVHYTl2dlh1NlF1TVVlSS0xOXNJRk82N0RNa2VJck14ZVhPdlpJRjJkRWQxeERaanZzSTdKLXlSaHZ5eFlKOWMzZU8wNGViQzlZc1FnNEhfY29jeDJ5bU9fMnplYy1PWkp2SlZPcGVYRTJmNXFNY3RPWlBLSFFtYTBuYmd0aEdGOGJvS0Z4MGw5bUk?oc=5" target="_blank">IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches
Frontiersgeneral

Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOR2dacmdsVy03RHQ0c3VQZ1Y5NFM2RnVGMEZXcGdleU96VENEcEdKY0dRSVAzb1JCdm45NlBYeGNFRVdFdGI1cDczUHloWXFHMUVSNGNyaGJ5ajBJbHVQRXRVRWM0TnlwTzR1Z0hOTl9QeXAyQlFBVFo3Z1JJZVZweXB0ZVZwd1RpUVBZWg?oc=5" target="_blank">Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Loss of Bone Marrow Minimal Residual Disease Negativity Predicts Future Relapse in Multiple Myeloma
Hematology Advisorgeneral

Loss of Bone Marrow Minimal Residual Disease Negativity Predicts Future Relapse in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOUVlEaWFVZ0RTWWI5TFd6eWh6TzdKMG9CcjR4TkxvWDUzYlcybjhvOEl2OFhSTTdHN21EUFJISnhjUVNRWFJFQ0Q4MHg2VmdvQUNpMmVRbUxLejcwdnNocmQzVXFqTGdIMWROcmViSkIyUjZfa0l2Z056TW13U0JGeFdUNFFXeW93RG1zMGp2YXlkUFFTRFN0U3lSQTF2V1hpcWxNdzZiWUVPVk5FcEluVnZaby05VDhGOU1hLXZwMzFGT0tTQXZndi1RLTZWdw?oc=5" target="_blank">Loss of Bone Marrow Minimal Residual Disease Negativity Predicts Future Relapse in Multiple Myeloma</a>  <font color="#6f6f6f">Hematology Advisor</font>

Read Full StoryMore like this
Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial
CancerNetworkgeneral

Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxOX0EzdXJMY0pITHNCS28xTHhkM1hVblJnS3dIMFJoakNIVmJucGlPQ1g5MVplUnJaWDNfZDRfdC1VbXdlazZKS05MZDdnODFWemVIOEVzeVZxeDl1bFlLcWduQkZxUHZzX053b3dkRnktWVNiRm1ySXdXUDRqVHZSbDM5SzYybHhETGxRYmlKOE4wa0NEQlBxQkxYTUxEQkl6ZWZvNWdKdHFWYUhwM3E4R0ZLd3hRVm1FUHh4YkhvMTRfYTljN3RZbA?oc=5" target="_blank">Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma: The CAR-PRISM Phase 2 Trial</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma
Targeted Oncologygeneral

CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNX3ZLMW1HNlNyNklTVWo1eFplNXJRNjAyV1JBVHg5NTk3SzJxOXdvRWNWZm96eTQzbjhSVGdRclZjRVV2eWk5NWswR0tZeGRoVkVYRzlPai1OZjVaM1U2eHMyTjNRMDh6eTVFZGk0XzZ0N2gzdFNTMXBhQlNMYlNKVHk4QXBIdjQ0NEJlNmRUdnJORlQtSHIwQ1FBZ0xoRVBpVDN3dzl2UmlSNG5t?oc=5" target="_blank">CEPHEUS Data Show Deeper MRD Response With D-VRd in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma
Naturegeneral

Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1INFF6TGZZUm5vMllVQVZmR2lLZ3I4V0FxTy1lSTNEejh6OFB5bVB5bFRodW43MEdFQjh3dnFOTXhsM2E1Nk5tbjBNa3MxdngtcmU3bzJEQlJkV3FTMllj?oc=5" target="_blank">Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Sustained minimal residua" — Live Google News Trends & Headlines